My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal
   Program
   Organisers
   Abstracts
   Participants

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland


2016
   Lisboa, Portugal


A-01
Registration at the conference venue
Tuesday 14:00-18:00
A-02
Opening ceremony and welcome reception
Tuesday 19:30-21:00
B-01
Registration at the conference venue
Wednesday 08:00-08:45
B-02
Welcome and Introduction
Wednesday 08:45-09:00
B-03 Nigel Klein
A biological perspective on immune response to drug treatment (intended and unintended effects)
Wednesday 09:00-09:40
B-04 Hans Peter Grimm
Intricate PK and PD for the novel immunocytokine CEA-IL2v and their pre-clinical to clinical translation
Wednesday 09:40-10:00
B-05 Kirill Peskov
Investigation of anti-CTLA-4 immuno-oncology therapy through a quantitative systems pharmacology model
Wednesday 10:00-10:20
B-06
Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter
Wednesday 10:20-11:40
B-07 Kapil Gadkar
A Six-Stage Workflow for Robust Application of Systems Pharmacology
Wednesday 11:40-12:00
B-08 Rob van Wijk
The zebrafish as model for translational systems pharmacology: expanding the allometric scale in vertebrates with five orders of magnitude
Wednesday 12:00-12:20
B-09
Lunch
Wednesday 12:20-13:50
B-10 Shasha Jumbe
Introduction to the Gates' Healthy Birth, Growth & Development knowledge integration project
Wednesday 13:50-14:05
B-11 Louise Ryan
Trajectory modelling based on early childhood longitudinal growth data
Wednesday 14:05-14:45
B-12 Niclas Jonsson
Determinants for physical growth patterns in low- and middle-income countries
Wednesday 14:45-15:05
B-13 Nick Holford
Announcement of WCoP 2016
Wednesday 15:05-15:10
B-14
Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter
Wednesday 15:10-16:40
B-15 Mélanie Wilbaux
Characterizing and Forecasting Individual Weight Changes in Term Neonates
Wednesday 16:40-17:00
B-16 Nick Holford
Growth and decline of body size and composition – Prediction of the transition from pre-diabetes to Type 2 diabetes in humans
Wednesday 17:00-17:20
B-18 Thi Huyen Tram Nguyen
The paradox of highly effective sofosbuvir combo therapy despite slow viral decline
Wednesday 17:40-18:00
B-19 Rik Schoemaker
Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children
Wednesday 18:00-18:20
B-20
Special surprise...
Wednesday 18:30-18:50
C-01 Elin Svensson
Bedaquiline's exposure-response relationship revealed through modeling of mycobacterial load
Thursday 08:45-09:10
C-02 Solène Desmée
Joint modelling for nonlinear longitudinal PSA kinetics and survival data in metastatic prostate cancer patients
Thursday 09:10-09:35
C-03 Stein Schalkwijk
A physiologically-based population pharmacokinetic analysis to assess a lower efavirenz dose of 400 mg once daily in HIV-infected pregnant women.
Thursday 09:35-10:00
C-04
Presentation of Lewis Sheiner student session awards
Thursday 10:00-10:05
C-05
Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter
Thursday 10:05-11:30
C-06 Matts Kågedal
Time-to-Event Modeling of Peripheral Neuropathy – Platform Mega-Analysis of Eight vc-MMAE Antibody-Drug Conjugates (ADCs)
Thursday 11:30-11:50
C-07 Lucy Hutchinson
Mixed-effect modelling of transient tumour growth dynamics following anti-angiogenic therapy
Thursday 11:50-12:10
C-08 Maria Luisa Sardu
Modelling of classified individual tumor lesions in metastatic colorectal cancer (mCRC) patients using delay differential equations.
Thursday 12:10-12:30
C-09
Lunch
Thursday 12:30-13:50
C-10 Robert Bauer
An overview of Estimation-Maximization Algorithms Used in Population Analysis Methods
Thursday 13:50-14:35
C-11 Brian Corrigan
Announcement of ACoP7
Thursday 14:35-14:40
C-12
Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter
Thursday 14:40-16:00
C-13 Yevgen Ryeznik
Adaptive dose finding for time-to-event outcomes with adaptive choice of patient number based on response rate
Thursday 16:00-16:20
C-14 Sebastian Wicha
A general pharmacodynamic interaction model based on the Bliss Independence criterion
Thursday 16:20-16:40
C-15 Martin Fink
Improving priors for human mAb linear PK parameters by using half-lives from pre-clinical studies
Thursday 16:40-17:00
C-16 David McDougall
The Impact of Model Selection for Personalised Dosing
Thursday 17:00-17:20
C-17
Social event: Buses depart from the Conference Venue at 19:30
Thursday 20:00-01:00
D-01 Lutz Harnisch
Modelling and simulation of neurological endpoints (modified Rankin Scale [mRS] and National Institute of Health Stroke Scale [NIHSS]) to aid clinical trial design in intracerebral hemorrhage (ICH)
Friday 09:00-09:20
D-02 Oliver Sander
Model-based development of the secukinumab dosing regimen for the treatment of moderate-to-severe chronic plaque psoriasis
Friday 09:20-09:40
D-03 Rasmus Vestergaard Juul
Repeated time to event modelling of opioid consumption in postoperative pain
Friday 09:40-10:00
D-04 Thu Thuy Nguyen
Limited sampling strategy for a population pharmacokinetic modelling of cocktail of phenotyping drugs
Friday 10:00-10:20
D-05
Preview of PAGE2017
Friday 10:20-10:30
D-06
Coffee break
Friday 10:30-11:00
D-07 Sylvie Retout
How disease modeling and model-based meta-analyses contributed to understanding the path forward after dose discontinuation of a Phase III study in Alzheimer's disease
Friday 11:00-11:20
D-08 Marc Vandemeulebroecke
A longitudinal Item Response Theory model to characterize cognition over time in elderly subjects
Friday 11:20-11:40
D-09 Simon Buatois
Utilizing the items from the MDS-UPDRS score to increase drug effect detection power in de novo idiopathic Parkinson's disease patients
Friday 11:40-12:00
D-10
Closing remarks
Friday 12:00-12:10
D-11
Audience input for potential PAGE2017 topics
Friday 12:10-12:30
I-01 Thomas Dumortier
Using extrapolation to support a pediatric investigational plan: an application in liver transplantation development
Wednesday 10:20-11:40
I-02 Mike Dunlavey
A new language for complex ODE models
Wednesday 10:20-11:40
I-03 Sulav Duwal
Top-down and Bottom-Up modelling approaches in Systems Pharmacology: Understanding clinical efficacy of NRTIs against HIV-1
Wednesday 10:20-11:40
I-04 Lisa Ehmann
Pharmacokinetics of meropenem in critically ill patients with varying renal function
Wednesday 10:20-11:40
I-05 Miro Eigenmann
PBPK modeling approach to study the impact of lymph flow on the biodistribution of therapeutic antibodies
Wednesday 10:20-11:40
I-06 Raouf EL Cheikh
A New Protocol for the Administration of Etoposide–Cisplatin in Metastatic Small Cell Lung Cancer
Wednesday 10:20-11:40
I-07 Yumi Emoto-Yamamoto
Development of a generic model for brain distributional pharmacokinetics and its translation to clinical data
Wednesday 10:20-11:40
I-08 Gregory Ferl
Mechanistic model of amyloid beta (Aß) and anti-Aß mAb dynamics
Wednesday 10:20-11:40
I-09 Eric Fernandez
Modelling and translating head and neck radiation therapy on all three levels: in vitro, in vivo and clinical
Wednesday 10:20-11:40
I-10 Natalie Filmann
Comparing the individual and the population approach in fitting heterogeneous PK/PD data of patients with chronic hepatitis B after liver transplantation
Wednesday 10:20-11:40
I-11 Linda Franken
Pharmacokinetics of midazolam and its metabolites in terminally ill adult patients
Wednesday 10:20-11:40
I-12 Jonathan French
A case study in comparing cognitive development across populations
Wednesday 10:20-11:40
I-13 Nicolas Frey
Model-based meta-analysis of amyloid plaque reduction in Alzheimer’s disease patients to identify new Phase 3 doses and dosing regimens for Gantenerumab
Wednesday 10:20-11:40
I-14 Aline Fuchs
Simulations to simplify gentamicin dosing regimens for neonates and young infants when referral is not possible in developing countries
Wednesday 10:20-11:40
I-15 Saskia Fuhrmann
Generic PBPK model to predict preclinical and clinical PK of antibodies
Wednesday 10:20-11:40
I-16 María García-Cremades
A comparison of different model-based approaches to scale preclinical to clinical tumour growth inhibition in gemcitabine-treated pancreatic cancer
Wednesday 10:20-11:40
I-17 Peter Gennemark
Unravelling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor-antidote) using mouse data
Wednesday 10:20-11:40
I-18 Eva Germovsek
Pharmacokinetic-pharmacodynamic (PKPD) modelling of meropenem in plasma and cerebrospinal fluid (CSF) in infants with late-onset sepsis and/or bacterial meningitis
Wednesday 10:20-11:40
I-19 Andy Gewitz
PK/PD Modeling of Tuberculosis for Identification of Biomarkers Associated with Treatment Duration
Wednesday 10:20-11:40
I-20 Ekaterina Gibiansky
Population Pharmacokinetic of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Other Indolent Non-Hodgkin’s Lymphoma (iNHL) Subtypes, Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL)
Wednesday 10:20-11:40
I-21 Leonid Gibiansky
vc-MMAE antibody-drug conjugates: a unified model describes pharmacokinetics of eight different compounds
Wednesday 10:20-11:40
I-22 Anais Glatard
Influence of UGT2B7 polymorphism on varenicline clearance in a cohort of smokers from the general population
Wednesday 10:20-11:40
I-23 Britta Goebel
Modeling & Simulation of Long-Term Body Weight Loss during Obesity Pharmacotherapy
Wednesday 10:20-11:40
I-24 Bojana Golubovic
Population modelling of sirolimus data available from routine therapeutic drug monitoring
Wednesday 10:20-11:40
I-25 Ignacio Gonzalez
Assessment of in vitro dissolution specifications based on an IVIVC and in vivo bioequivalence criteria
Wednesday 10:20-11:40
I-26 Verena Gotta
Characterizing age-dependency of cytokine levels in healthy children
Wednesday 10:20-11:40
I-27 Gopichand Gottipati
Item Response Modeling to Leverage Data from Historical Parkinson’s Disease Trials while Integrating Data from a Newer Version of the Clinical Endpoint
Wednesday 10:20-11:40
I-28 Sebastiaan Goulooze
Monte-Carlo simulations of sunitinib therapeutic drug monitoring in patients with gastrointestinal stromal tumours.
Wednesday 10:20-11:40
I-29 Sylvain Goutelle
A nonparametric, multiple-model approach to optimize initial dosing and attainment of a target exposure interval: application to busulfan in pediatrics
Wednesday 10:20-11:40
I-30 Joachim Grevel
Exposure-response analysis for efficacy and safety of sorafenib in patients with differentiated thyroid carcinoma (DTC)
Wednesday 10:20-11:40
I-31 Monia Guidi
Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients
Wednesday 10:20-11:40
I-32 Elham Haem
Adjusted adaptive lasso for covariate model building in nonlinear mixed effects models
Wednesday 10:20-11:40
I-34 Janelle Hajjar
Modeling Duchenne muscular dystrophy disease progression as assessed by the 6-minute walk test
Wednesday 10:20-11:40
I-35 Nayoung Han
Dose estimation based on population pharmacokinetic/pharmacogenetic modeling for enteric-coated mycophenolate sodium in kidney transplant recipients
Wednesday 10:20-11:40
I-36 Nina Hanke
Physiologically-based Pharmacokinetic Modeling of Rifampin Drug-Drug Interactions with Midazolam and Digoxin
Wednesday 10:20-11:40
I-37 Fangran Hao
Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft
Wednesday 10:20-11:40
I-38 Paul Healy
Model-based dose selection of tocilizumab for the prevention of reperfusion injury.
Wednesday 10:20-11:40
I-39 Michael Heathman
A Categorical Time Course PKPD Model Describing the Effect of Ixekizumab on Improvement from Baseline in Psoriasis Area and Severity Index (PASI) score in Patients with Moderate to Severe Plaque Psoriasis
Wednesday 10:20-11:40
I-40 Andrea Henrich
PK/PD model extension to characterise bone marrow exhaustion in cancer patient making use of a prior paclitaxel PK model
Wednesday 10:20-11:40
I-41 Christoph Hethey
Impact of the intracellular ribosomal concentration on in vitro bacterial growth kinetics and the antibacterial effect of linezolid on S. aureus in time-kill assays
Wednesday 10:20-11:40
I-42 Jennifer Hibma
Population Pharmacokinetic/Pharmacodynamic Evaluation of the Effect of Inotuzumab Ozogamicin on QT Intervals in ALL and NHL Patients
Wednesday 10:20-11:40
I-43 Eef Hoeben
Viral Kinetic Modeling of HCV RNA Decline during Treatment with Simeprevir in Combination with Sofosbuvir
Wednesday 10:20-11:40
I-44 Christian Hollensen
Estimation of random variance in NONMEM using different approaches
Wednesday 10:20-11:40
I-45 Xiao Hu
Population pharmacokinetic analysis of fampridine in Japanese patients with multiple sclerosis in a Phase 3 study
Wednesday 10:20-11:40
I-47 Stephen Duffull
The influence of parameterisation on local identifiability
Wednesday 10:20-11:40
I-48 Manuel Ibarra
Pharmacokinetic characterization of naphtalophos in lambs by modelling blood acetylcholinesterase activity, a K-PD model
Wednesday 10:20-11:40
I-49 Moustafa Ibrahim
Importance of hot glucose for the integrated glucose-insulin minimal model
Wednesday 10:20-11:40
I-50 Diane-Charlotte Imbs
Modeling and simulation for improving the efficacy of the combination between antiangiogenic and chemotherapy in Non Small Cell Lung Cancer
Wednesday 10:20-11:40
I-51 Itziar Irurzun-Arana
Attractor analysis of Boolean models for Systems Pharmacology Networks
Wednesday 10:20-11:40
I-52 Swati Jaiswal
Pharmacokinetic-Pharmacodynamic modeling of miltefosine in Leishmania donovani infected Golden Syrian Hamsters
Wednesday 10:20-11:40
I-53 Masoud Jamei
Time variation in the fractional contribution of an enzyme to elimination of a victim drug can explain differences in DDI susceptibility following single and multiple dosing
Wednesday 10:20-11:40
I-54 Félix Jaminion
Use of a drug-drug interaction study with itraconazole to quantify the effects of an NME on QT interval duration
Wednesday 10:20-11:40
I-55 Carl Johansson
Omeprazole dose recommendation in pediatric patients aged 1-11 months with erosive esophagitis
Wednesday 10:20-11:40
I-56 Jong Bong Lee
Predicted versus experimental permeability data for incorporation into GastroPlus™ for modelling and simulations
Wednesday 10:20-11:40
I-57 Daniel Jonker
Personalized dosing of a novel recombinant human FSH, follitropin delta, based on individual patient characteristics
Wednesday 10:20-11:40
I-58 Marija Jovanovic
Population pharmacokinetic model of topiramate and its major metabolite in adult epileptic patients
Wednesday 10:20-11:40
I-59 Matts Kågedal
Selection of exposure metrics AUC, Cmax or Cmin in exposure response analyses – a simulation study.
Wednesday 10:20-11:40
I-60 Tatiana Karelina
Clinical trial simulation and hypothesis testing using amyloid pathology longitudinal translational model
Wednesday 10:20-11:40
I-61 Anhye Kim
Population Pharmacokinetic/Pharmacoynamic Models to evaluate the positive and delayed effect of escitalopram on QT prolongation
Wednesday 10:20-11:40
I-62 Anke Kip
Population pharmacokinetics of plasma and intracellular miltefosine concentrations in cutaneous leishmaniasis patients
Wednesday 10:20-11:40
I-63 Lena Klopp-Schulze
Tamoxifen and endoxifen pharmacokinetics: Exploration of differences in model performance using simulations
Wednesday 10:20-11:40
I-64 Katrine Knøsgaard
A model-based approach for joint analysis of pain intensity and opioid consumption in postoperative pain
Wednesday 10:20-11:40
I-65 Gilbert Koch
Facilitate treatment adjustment after accidental overdosing: pharmacometric modelling to support clinical practice
Wednesday 10:20-11:40
I-66 Anders Kristoffersson
Design and Interim Evaluation of a Sparse Sampling Schedule for Estimation of Individual Colistin Pharmacokinetics
Wednesday 10:20-11:40
I-67 Anne Kuemmel
PECAN, a Shiny application for calculating confidence and prediction intervals for pharmacokinetic and pharmacodynamic models
Wednesday 10:20-11:40
I-68 Manish Kumar
Elucidating metabolic variations in gut microbiota during health and malnutrition based on genome scale metabolic modeling approach
Wednesday 10:20-11:40
I-69 Max Lagraauw
A population disease progression model for Amyotrophic Lateral Sclerosis – Results of the Treeway Summer Challenge 2015
Wednesday 10:20-11:40
I-70 Laure Lalande
Mathematical modeling and systems pharmacology of tuberculosis therapy with isoniazid
Wednesday 10:20-11:40
I-71 Silvia Maria Lavezzi
Structural and practical identifiability of some mPBPK-TMDD models
Wednesday 10:20-11:40
I-72 Jean Lavigne
Modeling and simulation of smear count after administration of Eurartesim® (piperaquine (PQ) tetraphosphate/dihydroartemisinin (DHA)) in infected patients with Plasmodium falciparum malaria
Wednesday 10:20-11:40
I-73 Mary Lavy
Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Natalizumab in Patients with Multiple Sclerosis (MS)
Wednesday 10:20-11:40
I-74 Robert Leary
An Improved Framework for Shrinkage Computations in NLME Population Models
Wednesday 10:20-11:40
II-01 Khaled Abduljalil
Simcyp Simulator within the DDMoRe Interoperability Framework – Proof of Concept Cases
Wednesday 15:10-16:30
II-02 João Abrantes
Population pharmacokinetic analysis of factor VIII activity following treatment with moroctocog alfa in moderate to severe haemophilia A subjects
Wednesday 15:10-16:30
II-03 Malidi Ahamadi
Population exposure –response analysis of “On-Off” time in Individuals with Parkinson Disease following Preladenant Treatment
Wednesday 15:10-16:30
II-04 Maurice Ahsman
Modelling and simulation of oral GnRH Antagonist TAK-385 and testosterone-lowering response in Prostate Cancer Patients to Optimize Trial Design and Dose Selection
Wednesday 15:10-16:30
II-05 Sihem Ait-Oudhia
A plateform PK/PD Model for Antibody Drug Conjugates Induced Myelosuppression
Wednesday 15:10-16:30
II-06 Ali Mohamed Ali
Population pharmacokinetics of the amodiaquine: pooling data across different studies to optimize dosing in neglected populations
Wednesday 15:10-16:30
II-07 Hesham Al-Sallami
Redefining normal variability of drug disposition
Wednesday 15:10-16:30
II-08 Silvana Alvariza
Autoinduction of phenytoin hepatobiliary secretion as a mechanism for its nonlinear pharmacokinetics
Wednesday 15:10-16:30
II-09 Claire Ambery
Balancing efficacy and risk: A case study of Phase 2 dose selection for an anti-inflammatory drug
Wednesday 15:10-16:30
II-10 Yasunori Aoki
Model Averaging and Selection methods for model structure and parameter uncertainty quantification
Wednesday 15:10-16:30
II-11 Manel Aouri
Population pharmacokinetics analysis of dolutegravir in HIV-1 infected individuals
Wednesday 15:10-16:30
II-12 Hyun-moon Back
Development of QT prolongation model in guinea pig with hERG assay-in vivo PK- in-vivo QT effect to guide decision making in early drug discovery
Wednesday 15:10-16:30
II-13 Suruchi Bakshi
Explaining the unexpected multi-stationarity in a nonlinear model of prolactin response to dopamine D2 receptor antagonists
Wednesday 15:10-16:30
II-14 Violeta Martínez
Target evaluation for Inflammatory Bowel Disease (IBD) using a Systems Pharmacology model
Wednesday 15:10-16:30
II-15 Kathryn Ball
Prediction of food effect in the Chinese population using a PBPK model developed in a Caucasian population
Wednesday 15:10-16:30
II-16 Catalina Barceló
Population pharmacokinetics analysis of elvitegravir and cobicistat in HIV-1 infected individuals
Wednesday 15:10-16:30
II-17 Charlotte Barker
Simultaneous modelling of antimicrobial pharmacokinetic data from birth to adolescence: using different penicillins to inform a common maturation function
Wednesday 15:10-16:30
II-18 Ana Bastos
Using modeling and simulation to design and evaluate dosing strategies for temocillin in haemodialysis patients
Wednesday 15:10-16:30
II-19 Levy Batista
Mixed-effects ARX model identification of dynamical systems
Wednesday 15:10-16:30
II-20 Brendan Bender
An integrated pharmacokinetic-pharmacodynamic modeling analysis of T-DM1–induced thrombocytopenia and hepatotoxicity in patients with HER2-positive metastatic breast cancer
Wednesday 15:10-16:30
II-21 Andrzej Bienczak
Semi-physiological pharmacokinetic/pharmacogenetic model with circadian rhythm for the characterisation of nevirapine pharmacokinetics in African children.
Wednesday 15:10-16:30
II-22 Roberto Bizzotto
Mixed-effect deconvolution: a new method applied to oral paracetamol absorption
Wednesday 15:10-16:30
II-23 Henrik Bjugård Nyberg
Dismounting Saddles on the Likelihood Surface
Wednesday 15:10-16:30
II-24 Dimitra Bon
PK-PD-VK modeling for hepatitis C treatment with the CI and Generalized multiscale model.
Wednesday 15:10-16:30
II-25 Charlotte Bon
A target mediated cellular uptake model to assess the asialogycoprotein receptor shuttle capacity in hepatocytes
Wednesday 15:10-16:30
II-26 Irina Bondareva
External validation and predictability of nonlinear models for changes in steady–state pharmacokinetics (PK) of carbamazepine (CBZ) and valproate (VPA) due to antiepileptic drug-drug interactions using sparse therapeutic drug monitoring (TDM) data
Wednesday 15:10-16:30
II-27 Jennifer Bonner
Building of virtual geriatric cancer populations for physiologically-based pharmacokinetic modelling and simulation in cancer patients greater than 70 years of age
Wednesday 15:10-16:30
II-28 Elisa Borella
Development and integration of the WinBUGS connector in the DDMoRe Interoperability Framework
Wednesday 15:10-16:30
II-29 Agnieszka Borsuk-De Moor
Population pharmacokinetics of sufentanil after epidural and intravenous administration in children and infants
Wednesday 15:10-16:30
II-30 Margreke Brill
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis
Wednesday 15:10-16:30
II-31 Hannah Britz
Physiologically-Based Pharmacokinetic (PBPK) Modeling of the Dronedarone Drug-Drug Interaction with Digoxin
Wednesday 15:10-16:30
II-32 Jantine Brussee
Predictive performance of a CRP and organ failure based pharmacokinetic model for midazolam in critically ill children across external datasets in neonates, children and adults
Wednesday 15:10-16:30
II-33 Vincent Buchheit
Added value of the Data Scientist role in a Clinical Pharmacometric group
Wednesday 15:10-16:30
II-34 Charles Burdet
Joint modeling of plasma and fecal moxifloxacin pharmacokinetics in healthy volunteers
Wednesday 15:10-16:30
II-35 Elisa Calvier
Allometric scaling of clearance in paediatrics: when does the magic of 0.75 fade?
Wednesday 15:10-16:30
II-36 Tim Cardilin
Extending the Tumor Static Concentration curve to average doses – a combination therapy example using radiation therapy
Wednesday 15:10-16:30
II-37 Luzelena Caro
Population Pharmacokinetics Modeling Characterizes the Higher Grazoprevir Exposure in Japanese Compared to Non-Japanese HCV-Infected Patients
Wednesday 15:10-16:30
II-38 Letizia Carrara
Methods and tools for multiscale modelling in Systems Pharmacology: a review
Wednesday 15:10-16:30
II-39 Jason Cawley
Competitive brain and body growth model
Wednesday 15:10-16:30
II-40 Pascal Chanu
A model to predict progression free survival in patients with previously untreated HER2-positive progressive or recurrent locally advanced or metastatic breast cancer based on tumor growth inhibition metrics
Wednesday 15:10-16:30
II-41 Aziz Chaouch
Building up a posteriori percentiles for Therapeutic Drug Concentration Monitoring
Wednesday 15:10-16:30
II-42 Jonathan Chard
Pharmacometrics workflow: standards for provenance capture and workflow definition
Wednesday 15:10-16:30
II-43 Christophe Chassagnole
Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour
Wednesday 15:10-16:30
II-44 Chunli Chen
Assessment of Pharmacodynamic Interactions in the Mycobacteria Tuberculosis Infected Mouse using The Multistate Tuberculosis Pharmacometric Model and the General Pharmacodynamic Interaction Model
Wednesday 15:10-16:30
II-45 Charles Chen
Comparison of Recursive Partitioning Analysis and Receiver Operating Characteristic (ROC) Analysis for Patient Identification
Wednesday 15:10-16:30
II-46 Maxwell Tawanda Chirehwa
Semi-mechanistic pharmacokinetic model for Isoniazid and Acetyl isoniazid in a cohort of TB/HIV co-infected patients
Wednesday 15:10-16:30
II-47 Hyewon Chung
Population pharmacokinetics of F-ara-A after fludarabine administration in pediatric hematopoietic stem cell transplantation patients
Wednesday 15:10-16:30
II-48 Laurent Claret
A model to predict progression-free survival in patients with renal cell carcinoma based on week 8 change in tumor size
Wednesday 15:10-16:30
II-49 Yumi Cleary
Physiologically –based pharmacokinetic (PBPK) and population PK (PPK) modeling for basimglurant - assessment of predicted variability by the PBPK model and its utility
Wednesday 15:10-16:30
II-50 Oskar Clewe
Pre-clinical Susceptibility Characterization and Pharmacodynamic Interaction Assessment Using the Multistate Tuberculosis Pharmacometric Model
Wednesday 15:10-16:30
II-51 Pieter Colin
Propofol breath monitoring as a potential tool to improve the prediction of intraoperative plasma concentrations
Wednesday 15:10-16:30
II-52 Emmanuelle Comets
Operational characteristics of saemix, an R package implementing the SAEM algorithm
Wednesday 15:10-16:30
II-53 Valerie Cosson
Amyloid related imaging abnormalities (ARIA): Time to event modeling to identify new Phase 3 doses and dosing regimens for Gantenerumab
Wednesday 15:10-16:30
II-54 Sinziana Cristea
Maturation of Glomerular Filtration throughout the paediatric age-range; a comparison of different functions
Wednesday 15:10-16:30
II-55 Damien Cronier
PK/PD Modeling of Overall and Progression-Free Survival in Advanced Soft Tissue Sarcoma Patients Treated With Olaratumab in Combination with Doxorubicin.
Wednesday 15:10-16:30
II-56 Salvatore D'Agate
Optimisation of weight-banded dosing regimens of amoxicillin in neonates and young infants with sepsis
Wednesday 15:10-16:30
II-57 Andre Dallmann
Validation of a Population Physiologically-Based Pharmacokinetic Model for Pregnant Women
Wednesday 15:10-16:30
II-58 Fabrizia D'Antonio
Effect of psychotic subtypes on cognitive trajectories in Alzheimer’s disease Neuroimaging Initiative ADNI2.
Wednesday 15:10-16:30
II-59 Pieter De Cock
piperacillin-tazobactam pharmacokinetics in critically ill children: implications on adequate dosing regimens
Wednesday 15:10-16:30
II-60 Miné De Kock
Pharmacokinetics of Sulfadoxine and Pyrimethamine for intermittent preventive treatment of malaria during Pregnancy and after delivery.
Wednesday 15:10-16:30
II-61 Bernardo de Miguel Lillo
Modeling the dynamics of alanine aminotransferase in advanced cancer patients treated with kahalalide F
Wednesday 15:10-16:30
II-62 Mailys De Sousa Mendes
A physiologically based pharmacokinetic model for a drug metabolized by several CYP450 during pregnancy
Wednesday 15:10-16:30
II-63 Aurelia de Vries Schultink
Pharmacokinetics of MCLA-128 in cynomolgus monkeys and extrapolation to humans to support selection of first-in-human dose
Wednesday 15:10-16:30
II-64 Brenda de Winter
Pharmacokinetics of Pentobarbital in Pediatric Status Epilepticus Patients
Wednesday 15:10-16:30
II-65 Wilbert de Witte
High drug-target association rates increase the duration of in vivo target occupancy
Wednesday 15:10-16:30
II-66 Amelia Deitchman
Tetracycline against Pseudomonas aeruginosa: Pharmacokinetic/Pharmacodynamic Modeling of In Vitro Time-Kill Curves
Wednesday 15:10-16:30
II-67 Laurence Del Frari
Predicting human pharmacokinetics of monoclonal antibodies by allometric translation from preclinical data: a case study
Wednesday 15:10-16:30
II-68 Ivan Demin
Guidance on dose-finding studies for biostatisticians and pharmacometricians: a Pharmacometrics perspective
Wednesday 15:10-16:30
II-69 Paolo Denti
Population Pharmacokinetics of Levofloxacin in South African children.
Wednesday 15:10-16:30
II-70 Christiane Dings
Pharmacokinetic and Pharmacodynamic Modeling of Acetylsalicylic Acid and its Major Metabolite Salicylic Acid
Wednesday 15:10-16:30
II-71 Aris Dokoumetzidis
A PBPK model for Tc99m-Tetrofosmin in humans from SPECT imaging data.
Wednesday 15:10-16:30
II-72 Thomas Dorlo
Translational PKPD modeling framework to assess the predictive performance of a preclinical visceral leishmaniasis hamster model
Wednesday 15:10-16:30
II-73 Anne-Gaelle Dosne
Robust QT prolongation assessment using model-averaging
Wednesday 15:10-16:30
II-74 Erwin Dreesen
Anti-drug antibodies, low serum albumin and high C-reactive protein increase infliximab clearance in patients with inflammatory bowel disease: a population pharmacokinetic study of the TAXIT trial
Wednesday 15:10-16:30
II-75 Stefanie Drescher
An Integrated Model for Glucose and Insulin Regulation in Bariatric Surgery Patients following Intravenous Glucose Tolerance Test
Wednesday 15:10-16:30
II-76 Hélder Duarte
Amikacin in premature newborn: a new therapeutic proposal from a PopPK model
Wednesday 15:10-16:30
II-77 Vincent Dubois
Joint modelling of pain intensity and informative dropout in moderate to severe chronic pain patients
Wednesday 15:10-16:30
III-01 Giulia Lestini
Model-based optimal robust design in pharmacometrics
Thursday 10:05-11:30
III-02 Lia Liefaard
Mixed effects modelling of dose-response cough count data
Thursday 10:05-11:30
III-03 Andreas Lindauer
Time-to-seizure modeling of the antiepileptic drug lacosamide used in monotherapy
Thursday 10:05-11:30
III-04 Ling Xue
Theory based PK-PD of S- and R-warfarin: influence of body size, composition and genotype
Thursday 10:05-11:30
III-05 Jesmin Lohy Das
Population pharmacokinetic and pharmacodynamic (PK/PD) modelling of emerging artemisinin resistance in Southern Myanmar
Thursday 10:05-11:30
III-06 Kurt Long
Identification of causal pathways determining the relationship between pathogen-specific infection and impaired growth among children < 59 months in Mirzapur, Bangladesh
Thursday 10:05-11:30
III-07 Dominik Lott
Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod
Thursday 10:05-11:30
III-08 Gaohua Lu
A Novel Mechanistic Approach to Predict the Steady State Volume of Distribution (Vss) using the Fick-Nernst-Planck Equation
Thursday 10:05-11:30
III-09 Sreenath M Krishnan
Population modeling of uni- and three- dimensional and density-based tumor measurements in gastro-intestinal stromal tumor (GIST) patients treated with imatinib
Thursday 10:05-11:30
III-10 Vincent Madelain
Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies against hemorrhagic fever viruses
Thursday 10:05-11:30
III-11 Mats Magnusson
Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis
Thursday 10:05-11:30
III-12 Adedeji Majekodunmi
Mechanistic modelling of naive CD4+ T cell homeostasis in HIV-infected children on anti-retroviral therapy
Thursday 10:05-11:30
III-13 Victor Mangas-Sanjuan
Exploring Inter-study variability in the context of modeling unperturbed xenograft data
Thursday 10:05-11:30
III-14 Vikash Mansinghka
BayesDB Marcro Indicator Explorer ensemble models for growth outcome country phenotyping
Thursday 10:05-11:30
III-15 Ben Margetts
Modelling Severe Human Cytomegalovirus Infections in an Immunocompromised Paediatric Patient Population
Thursday 10:05-11:30
III-16 Amelie Marsot
Population pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers
Thursday 10:05-11:30
III-17 Lisa Martial
Population PK model and pharmacokinetic target attainment of micafungin in ICU patients
Thursday 10:05-11:30
III-18 Emma Martin
Modelling based methods to account for dropout in xenograft experiments
Thursday 10:05-11:30
III-19 Jean-Marie Martinez
Modelling and simulation of alirocumab – Part 1: Population pharmacokinetic analysis using a Michaelis-Menten approximation of the target-mediated drug disposition model
Thursday 10:05-11:30
III-20 Paolo Mazzei
Population exposure-response modeling of oral nepadutant administration in infants with colic
Thursday 10:05-11:30
III-21 Litaty Céphanoée Mbatchi
Pharmacokinetics modelling of temsirolimus and its active metabolite
Thursday 10:05-11:30
III-22 Johanna Melin
Semi-mechanistic modelling of the nonlinear hydrocortisone pharmacokinetics to enable extrapolation into paediatric patients
Thursday 10:05-11:30
III-23 Evgeny Metelkin
Development of immune responce template forsystems pharmacology modeling of immunotherapy in oncology
Thursday 10:05-11:30
III-24 Jonathan Mochel
Pharmacodynamics of the renin-angiotensin aldosterone system and blood pressure in relation to food intake in dogs
Thursday 10:05-11:30
III-25 Shuhua Hu
Use of interim analysis to improve efficiency of clinical trial simulations in treatment comparison trial design studies
Thursday 10:05-11:30
III-26 Pablo Morentin Gutierrez
A population pharmacokinetic-pharmacodynamic model for AZD7687: Effects on plasma triacylglycerol after oral lipid tolerance test
Thursday 10:05-11:30
III-27 Michael Morimoto
A quantitative physiologic model of the interaction of nutrition and infection in determining the energy available for growth
Thursday 10:05-11:30
III-28 Samer Mouksassi
Primary microcephaly: do all roads lead to Rome?
Thursday 10:05-11:30
III-29 Morris Muliaditan
Prediction of the exposure of anti-tuberculosis drugs in lung tissue: implications for dose selection
Thursday 10:05-11:30
III-30 Zufar Muliukov
Modeling the effect of ranibizumab on central retinal thickness in patients with wet age-related macular degeneration
Thursday 10:05-11:30
III-31 Silke Gastine
Population Pharmacokinetics of Voriconazole in pediatric cancer patients - assessing new dosing strategies
Thursday 10:05-11:30
III-32 Cynthia Musante
The International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology: Developing a community and advancing a field
Thursday 10:05-11:30
III-33 Karin Nelander
Longitudinal dose-response modelling as primary analysis of a clinical study
Thursday 10:05-11:30
III-34 Xavier Nicolas
Modelling and simulation of alirocumab - Part 2: Population pharmacokinetic/pharmacodynamic analysis using an indirect response model to link drug concentrations with LDL-C
Thursday 10:05-11:30
III-35 Jaeseong Oh
Simultaneous population pharmacokinetic analysis of VVZ-149 and its active metabolite in healthy volunteers
Thursday 10:05-11:30
III-36 Boram Ohk
Population Pharmacokinetic modeling of Tacrolimus in Healthy Korean Subjects
Thursday 10:05-11:30
III-37 Andrés Olivares-Morales
Combining population with physiologically-based pharmacokinetic (PBPK) models for oral drug absorption: Predicting the segmental bioavailability differences of R-oxybutynin and its main metabolite using a middle out approach.
Thursday 10:05-11:30
III-38 Per Olsson Gisleskog
Predicting the effects of combining broadly neutralizing antibodies (bNabs) binding to different HIV viral epitopes
Thursday 10:05-11:30
III-39 Mohamed Omari
Modelling of glucose-insulin metabolism and its effect on the estrous cycle in bovine
Thursday 10:05-11:30
III-40 Sean Oosterholt
Model-based extrapolation and dosing recommendation for raxibacumab in children from birth to <18 years of age
Thursday 10:05-11:30
III-41 Stine Timmermann Ottesen
Analysing the contribution to receptor occupancy from active metabolites
Thursday 10:05-11:30
III-42 Shan Pan
Delineation of the treatment effect of methotrexate when used in combination therapy for rheumatoid arthritis
Thursday 10:05-11:30
III-43 Theodoros Papathanasiou
Population modelling of the synergistic effects of morphine and gabapentin in the rat: a response surface approach
Thursday 10:05-11:30
III-44 Zinnia Parra-Guillen
Pharmacokinetic analysis of midazolam and caffeine as probe drugs for cytochrome phenotyping in erlotinib treatment
Thursday 10:05-11:30
III-45 Sophie Peigne
Optimal design in the analysis of a clinical study in paediatric population
Thursday 10:05-11:30
III-46 Nathalie Perdaems
PK/PD modelling: a usefull tool to train people to better design in vivo chronic study in ob/ob mice
Thursday 10:05-11:30
III-47 Belén Pérez Solans
Markov model for tumor shrinkage effects of combination therapy in non-metastatic gastric cancer patients
Thursday 10:05-11:30
III-48 Alejandro Pérez-Pitarch
Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes Mellitus: Modelling Rate and Severity of Hypoglycemic Events
Thursday 10:05-11:30
III-49 Carlos Perez-Ruixo
Population pharmacokinetics and antiviral efficacy in neonatal lambs: evidence of rapid maturation and auto-induction drug effect in metabolic clearance
Thursday 10:05-11:30
III-50 Caroline Petit
Early phase dose-finding designs for bridging studies in pediatrics
Thursday 10:05-11:30
III-51 Séverine Petitprez
Population pharmacokinetic meta-analysis of seven antiretroviral drugs
Thursday 10:05-11:30
III-52 Tatiana Petukhova
Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics
Thursday 10:05-11:30
III-53 Thomas Peyret
A mechanistic maternal-fetal growth energy budget model
Thursday 10:05-11:30
III-54 Kimba Eddy Phongi
Population Pharmacokinetics of the Novel Antimalarial OZ439
Thursday 10:05-11:30
III-55 Chiara Piana
A novel model-based methodology for the evaluation of abuse potential
Thursday 10:05-11:30
III-56 Philippe Pierrillas
From mouse to human: comparison of interspecies translational strategies using integrative semi-mechanistic PK-PD models and PBPK-PD modeling to forecast efficacious clinical dose
Thursday 10:05-11:30
III-57 Teun Post
Application of a Shiny Workflow in Cardiovascular Effects Evaluations
Thursday 10:05-11:30
III-58 Manuel Prado-Velasco
Bridging the gap between open and specialized modelling tools in PBPK/PK/PD with PhysPK/EcosimPro modelling system: PBPK model of methotrexate and 6-mercaptopurine in humans with focus in reusability and multilevel modelling features
Thursday 10:05-11:30
III-59 Tim Preijers
In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients
Thursday 10:05-11:30
III-60 Claire Pressiat
Population pharmacokinetics of cotrimoxazole In West African HIV-infected children
Thursday 10:05-11:30
III-61 Angelica Quartino
Comparisons of Multiple Exposure-Response Methodologies in Oncology
Thursday 10:05-11:30
III-62 Rose Rachel
Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis.
Thursday 10:05-11:30
III-63 Christian Radke
Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis
Thursday 10:05-11:30
III-64 Christian Hove Rasmussen
Automated modeling workflow with LaTeX: using the new Pfizer Report Tool
Thursday 10:05-11:30
III-65 Isabel Reinecke
Changes in endogenous estradiol concentrations explain fluctuations in levonorgestrel (LNG) concentrations during continuous treatment with LNG releasing intravaginal rings
Thursday 10:05-11:30
III-66 Su-jin Rhee
A population pharmacokinetic analysis of levetiracetam in patients with epilepsy
Thursday 10:05-11:30
III-67 Sophie Rhodes
Previous BCG vaccination associated with variation in Mycobacterial-specific immune response: a modelling study
Thursday 10:05-11:30
III-68 Jakob Ribbing
Predicting reductions in chronic obstructive pulmonary disease (COPD) exacerbations from FEV1 – A model-based meta-analysis of literature data from controlled randomized clinical trials
Thursday 10:05-11:30
III-69 Camille Riff
First population pharmacokinetic model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery
Thursday 10:05-11:30
III-70 Clémence Rigaux
Parasitemia clearance modeling following Ferroquine administration in P. Falciparum infected patients
Thursday 10:05-11:30
III-71 Christelle Rodrigues
Population pharmacokinetics of oxcarbazepine and its 10-monohydroxy derivative in epileptic children
Thursday 10:05-11:30
III-72 Stefan Roepcke
Model-based analysis of monkey PK and PD data of a therapeutic cell depleting human monoclonal antibody – Preparing for clinical trials
Thursday 10:05-11:30
III-73 Amit Roy
Evaluating effectiveness of case-matching for exposure-response analysis
Thursday 10:05-11:30
III-74 Yue Ruan
Bayesian hierarchical model of glucose-insulin regulation over 12-week home use of closed-loop insulin delivery
Thursday 10:05-11:30
III-75 Muhammad Waqas Sadiq
Acute tolerance and rebound modelling with competitive interaction of mineralcorticoid driven urinary sodium excretion effects in the rat
Thursday 10:05-11:30
III-76 Richard Pugh
Data Science & Big Data: An Opportunity or a threat for Pharmacometrics?
Thursday 10:05-11:30
IV-01 Nikita Sakhanenko
New information-theory-based methods in the analysis of childhood development data
Thursday 14:40-16:00
IV-03 Celine Sarr
Capacities of NPDE, VPC and pvcVPC at detecting model misspecification: a simulation study of a PK model showed no apparent difference
Thursday 14:40-16:00
IV-04 Nina Scherer
Pharmacokinetic and Pharmacodynamic Modeling of Alirocumab and Evolocumab, two fully human monoclonal antibodies targeting PCSK9
Thursday 14:40-16:00
IV-05 Emilie Schindler
PK-PD modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size as predictors of overall survival in axitinib-treated metastatic renal cell carcinoma (mRCC) patients
Thursday 14:40-16:00
IV-06 Johannes Schropp
Development and implementation of drug-drug interaction mechanisms with target-mediated drug disposition
Thursday 14:40-16:00
IV-07 Partho Sen
Identification of foods with optimal nutritional value through data mining.
Thursday 14:40-16:00
IV-08 Ben Small
Changes in liver volume – a population-based approach to meta-analysis of paediatric, adult and geriatric populations
Thursday 14:40-16:00
IV-09 Kevin Smart
Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab
Thursday 14:40-16:00
IV-10 Mike Smith
Model Description Language (MDL) - a standard for model communication and interoperability
Thursday 14:40-16:00
IV-11 Victor Sokolov
A mechanistic PKPD model relating early asthmatic response to anti-leukotriene drug PK and biomarker levels in allergen challenge studies
Thursday 14:40-16:00
IV-12 Byungjeong Song
Application of different methodologies to explain the pharmacokinetic variabilities in pregnant women: Case study of Sulindac usage
Thursday 14:40-16:00
IV-13 Amaia Soraluce
Population pharmacokinetics of linezolid in critically ill patients and treatment probability of target attainment
Thursday 14:40-16:00
IV-14 Konstantina Soulele
A population pharmacokinetic study of salmeterol in asthmatic patients using two dry powder inhalers
Thursday 14:40-16:00
IV-15 Spyros Stamatelos
High-Resolution Image-based Computational Modeling of Breast Tumor Microvasculature
Thursday 14:40-16:00
IV-16 Oleg Stepanov
A quantitative systems pharmacology model to explore combination efficacy of immuno-oncology compounds: Effects of CXCR2 and PD-1 inhibitions
Thursday 14:40-16:00
IV-17 M. Elena Suarez Gonzalez
How delayed or missed doses influence efficacy of amoxicillin in outpatients with community-acquired pneumonia: A pharmacokinetic/pharmacodynamic simulation analysis
Thursday 14:40-16:00
IV-18 Siddharth Sukumaran
A quantitative systems pharmacology model for evaluating potential drugs for treatment of asthma
Thursday 14:40-16:00
IV-19 Robin Svensson
Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin
Thursday 14:40-16:00
IV-20 Eva Sverrisdóttir
Pharmacokinetic Metamodel of Morphine and Morphine-6-Glucuronide in Neonates and Adults
Thursday 14:40-16:00
IV-21 Maciej Swat
PharmML & SO - standards for encoding models and results in PMX and QSP
Thursday 14:40-16:00
IV-22 Yakovleva Tatiana
A systems pharmacology model of SGLT2 and SGLT1 inhibition to understand mechanism and quantification of urinary glucose excretion after treatment with Dapagliflozin, Canagliflozin and Empagliflozin
Thursday 14:40-16:00
IV-23 Paulo Teixeira
The Effect of Anthropometric Covariates on Clearance of Valproic Acid.
Thursday 14:40-16:00
IV-24 Rob ter Heine
The influence of erythrocyte accumulation on everolimus pharmacokinetics and pharmacodynamics in cancer patients
Thursday 14:40-16:00
IV-25 Adrien Tessier
Population Pharmacokinetic modelling and Pharmacogenetic analysis through a penalised regression approach for a molecule S
Thursday 14:40-16:00
IV-26 Donato Teutonico
Whole-body PBPK/PD modelling of ciprofloxacin and its anti-bacterial activity
Thursday 14:40-16:00
IV-27 Hoai-Thu Thai
Model-based drug development to support isatuximab dosing regimen selection in Phase II multiple myeloma patients
Thursday 14:40-16:00
IV-28 Anders Thorsted
Toxicokinetics of Endotoxin and its Induction of Pro-Inflammatory Cytokines Tumor Necrosis Factor a and Interleukin-6
Thursday 14:40-16:00
IV-29 Yingying Tian
Population pharmacokinetic analysis of everolimus in patients with solid tumors
Thursday 14:40-16:00
IV-30 Huybrecht T'jollyn
Pharmacokinetics of galantamine in plasma and brain for different intranasal formulations: an experimental in vivo study
Thursday 14:40-16:00
IV-31 Michel Tod
Comparison of the mechanistic static in vivo approach to a PBPK approach for prediction of metabolic drug-drug interactions.
Thursday 14:40-16:00
IV-32 Bruna Gaelzer Silva Torres
Population Pharmacokinetic Modeling of Ciprofloxacin Free Lung Concentrations in Healthy and Pseudomonas aeruginosa Biofilm Infected Wistar Rats
Thursday 14:40-16:00
IV-33 Elena Tosca
Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment
Thursday 14:40-16:00
IV-34 Mira Tout
Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia
Thursday 14:40-16:00
IV-35 Mirjam Trame
Development of a Mechanism Based Platform to Predict Cardiac Contractility and Hemodynamics in Conscious Dogs
Thursday 14:40-16:00
IV-36 Iñaki F. Trocóniz
Markov Model for Lithium Compliance Assessment
Thursday 14:40-16:00
IV-37 Max Tsai
Modelling of Pharmacokinetics and the Incidence of Adverse Events of the PDE-10A Inhibitor TAK-063
Thursday 14:40-16:00
IV-38 Ken-ichi Umehara
Assessment of DDI potential of ruxolitinib (INC424), a dual substrate of CYP3A4 and CYP2C9, using a verified PBPK model to support submissions to Health Authorities
Thursday 14:40-16:00
IV-39 Moreno Ursino
Evaluating phase I studies in small populations when incorporating pharmacokinetic information
Thursday 14:40-16:00
IV-40 Muhammad Usman
Population Pharmacokinetics of Meropenem in Elderly Patients: Dosing simulations based on Renal Function
Thursday 14:40-16:00
IV-41 Vladimir Vainstein
Dose translation of a hematopoietic acute radiation syndrome protection agent (recombinant human Interleukin-12) to humans.
Thursday 14:40-16:00
IV-42 Pyry Välitalo
A mathematical method assessing the informativeness of total test score on the basis of an item response theory model: A case study on pain in children
Thursday 14:40-16:00
IV-43 Willem van den Brink
Finding underlying longitudinal patterns in pharmaco-metabolomics data
Thursday 14:40-16:00
IV-44 Sven van Dijkman
Differentiation between Parkinson’s and Parkinson’s-like patients in MDS-UPDRS-based diagnosis
Thursday 14:40-16:00
IV-45 Tamara van Donge
Evaluating biosimilarity of monoclonal antibodies: comparison of population approach nonlinear mixed effects models to standard non-compartmental analysis
Thursday 14:40-16:00
IV-46 Michiel Van Esdonk
Development of a semi-population deconvolution method for the analysis of growth hormone profiles
Thursday 14:40-16:00
IV-47 Coen van Hasselt
The proof is in the pee: Population asparagus urinary odor kinetics.
Thursday 14:40-16:00
IV-48 Filippo Visco Comandini
Competitive brain and body growth model
Thursday 14:40-16:00
IV-49 Swantje Völler
Dose Recommendations for Recombinant Asparaginase in Children: A Population Pharmacokinetic Analysis
Thursday 14:40-16:00
IV-50 Max von Kleist
Systems pharmacology pipeline to assess NRTI-efficacy for repurposing as pre-exposure prophylactic compounds against HIV-1 infection
Thursday 14:40-16:00
IV-51 Camille Vong
Population Pharmacokinetics of Tofacitinib in Induction Studies for Moderate-to-Severe Ulcerative Colitis Patients
Thursday 14:40-16:00
IV-52 Veronika Voronova
Investigation of the diabetes-related metabolic memory phenomenon using a quantitative systems pharmacology approach
Thursday 14:40-16:00
IV-53 Ulrika Wählby Hamrén
Pharmacokinetics of the inhaled selective glucocorticoid receptor modulator AZD5423 following inhalation using different devices
Thursday 14:40-16:00
IV-55 Siyuan Wang
An integrated PK/PD model to link the frequency of cancer-stem-like cells to tumor volume for sunitinib combined with dopamine in the treatment of drug-resistant breast cancer
Thursday 14:40-16:00
IV-56 Sebastian Weber
Modeling Recurrent Safety Events in Drug Combinations using a Time-Varying Poisson Process
Thursday 14:40-16:00
IV-57 Janak Wedagedera
Investigating the Importance of Considering Inter-correlations of Cytochrome P450 Enzyme Abundances in Human Liver When Predicting Drug-Drug Interactions
Thursday 14:40-16:00
IV-58 Gustaf Wellhagen
Carbohydrate intake contribution to HbA1c
Thursday 14:40-16:00
IV-59 Thomas Wendl
Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients
Thursday 14:40-16:00
IV-60 Pawel Wiczling
A Bayesian approach for population pharmacokinetic modeling of dexmedetomidine during long-term infusion in critically ill pediatric patients.
Thursday 14:40-16:00
IV-61 Rixt Wijma
Population pharmacokinetics of meropenem during intermittent and continuous infusion in healthy volunteers
Thursday 14:40-16:00
IV-62 Jayson Wilbur
Zika microcephaly cutoffs revisited: A study of Non-parametric methods in fetal growth
Thursday 14:40-16:00
IV-63 Julia Winkler
Population pharmacokinetics of lacosamide to support intravenous dose adaptation in children with epilepsy
Thursday 14:40-16:00
IV-64 Jan-Georg Wojtyniak
A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome
Thursday 14:40-16:00
IV-65 Dan Wright
A population pharmacokinetic model for 51Cr EDTA, an isotopic biomarker for renal function: impact on carboplatin dosing.
Thursday 14:40-16:00
IV-66 Li Xia
Population pharmacokinetics of multiple oral doses of alcohol in humans using blood and breath measures
Thursday 14:40-16:00
IV-67 Gulbeyaz Yildiz Turkyilmaz
Investigating the ability of population PK models to characterize secondary exposure parameters
Thursday 14:40-16:00
IV-68 Younghoon Yoo
Pharmacokinetic Model for subconjunctival injection of bevacizumab in Rabbits.
Thursday 14:40-16:00
IV-69 Seonghae Yoon
Population pharmacokinetic analysis of oxcarbazepine in patients with epilepsy
Thursday 14:40-16:00
IV-70 Huixin Yu
Development of a pharmacokinetic model for pazopanib – a tyrosine kinase inhibitor used for the treatment of solid tumours
Thursday 14:40-16:00
IV-71 Jurij Zdovc
Pharmacokinetics of vancomycin in intensive-care patients
Thursday 14:40-16:00
IV-72 Fan Zhang
Population pharmacokinetic modeling of lamotrigine in Chinese subjects
Thursday 14:40-16:00
IV-74 Meng Zhaoling
Program-wise trial simulation assessing design and analysis options from proof of concept to dose ranging
Thursday 14:40-16:00
IV-75 Chenguang Zhou
Semi-mechanistic multiple-analyte pharmacokinetic model for a THIOMAB antibiotic conjugate against Staphylococcus aureus in mouse, rat and monkey
Thursday 14:40-16:00
IV-76 Li Zhu
Population Pharmacokinetic Modeling of Ulocuplumab, an anti-CXCR4 Monoclonal Antibody in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Multiple Myeloma
Thursday 14:40-16:00
IV-77 Kirill Zhudenkov
A Markov Chain model to characterize cataract progression and disease burden in the Russian Federation
Thursday 14:40-16:00
IV-78 Jochen Zisowsky
A Method to Perform PK-QT Analyses When Several Active Compounds or Metabolites Are Present
Thursday 14:40-16:00
S-01 Kajsa Harling
PsN and Xpose
During entire meeting
S-02 Gaohua Lu
Simcyp Simulator
During entire meeting
S-03 William Knebel
Metworx: high-performance cloud computing made simple
During entire meeting
S-04 Robert Bauer
NONMEM® 7.3 and 7.4 and PDx-Pop® 5.2
During entire meeting
S-05 Thomas Eissing
PK-Sim and MoBi for PBPK and Quantitative Systems Pharmacology Modeling and Simulation
During entire meeting
S-06 Michael Buchecker
IMPROVE – MODELING AND SIMULATION PLATFORM
During entire meeting
S-07 Will Haese-Hill
BAST: Clinical Trial Simulator and Service Supermarket
During entire meeting
S-08 Beatrice Attered
Reproducible Reporting
During entire meeting